Wall Street Zen upgraded shares of Azenta (NASDAQ:AZTA – Free Report) from a hold rating to a buy rating in a report published on Saturday morning,Wall Street Zen reports.
Other analysts have also recently issued research reports about the company. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 26th. Jefferies Financial Group lifted their price objective on Azenta from $44.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Needham & Company LLC boosted their price objective on Azenta from $37.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $47.60.
Read Our Latest Report on AZTA
Azenta Price Performance
Shares of NASDAQ:AZTA traded up $1.79 during midday trading on Friday, hitting $45.65. The company had a trading volume of 1,114,037 shares, compared to its average volume of 964,725. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -12.61 and a beta of 1.47. Azenta has a 12-month low of $15.93 and a 12-month high of $50.06. The company has a fifty day moving average of $36.52 and a two-hundred day moving average of $28.56.
Azenta (NASDAQ:AZTA – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17. The company had revenue of $167.09 million for the quarter, compared to analysts’ expectations of $160.16 million. Azenta had a positive return on equity of 1.41% and a negative net margin of 26.86%. Research analysts expect that Azenta will post 0.69 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Azenta during the second quarter valued at $192,152,000. Front Street Capital Management Inc. purchased a new position in shares of Azenta in the 2nd quarter worth approximately $33,212,000. American Capital Management Inc. bought a new position in shares of Azenta during the 2nd quarter valued at approximately $27,089,000. Bank of America Corp DE bought a new position in shares of Azenta during the 2nd quarter valued at approximately $17,058,000. Finally, Man Group plc bought a new position in shares of Azenta during the 2nd quarter valued at approximately $9,402,000. Institutional investors own 99.08% of the company’s stock.
Azenta News Roundup
These are some of the AZTA news items that stood out recently:
- Positive Sentiment: Needham raised its price target to $57 from $37 and maintained a Buy rating, signaling greater optimism about potential upside. Article: Needham Raises Azenta Price Target
- Positive Sentiment: Coverage highlighted commercial execution and new gene-synthesis capabilities as factors supporting Azenta’s outlook. KeyCorp’s estimates call for $0.69 EPS in FY2027 and $0.84 in FY2028; these are analyst forecasts, not company guidance. Article: Azenta Q3 Deep Dive
- Neutral Sentiment: After the sharp post-earnings advance, some investors took profits, contributing to a pullback; this may reflect near-term trading rather than a change in the company’s fundamentals. Article: Azenta Dips as Investors Book Profits
Azenta Company Profile
Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.
Further Reading
- Five stocks we like better than Azenta
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
